Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.
Also called NCT02933697
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 108 participants
- Registry
-
NCT02933697
-
- Other papers using this trial's data
- A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT02933697. Randomized; no masking; primary purpose treatment. Start 2017-06-20 (actual); primary completion 2022-07-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
- Acronym
- AXADIA
- Condition
- Atrial Fibrillation
- Condition
- End-stage Kidney Disease
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Phenprocoumon
- Lead sponsor
- Atrial Fibrillation Network
- Collaborator
- Bristol-Myers Squibb
- Collaborator
- Pfizer
Record details
- Record id
cardio:ct-nct02933697- Content hash
d458e35aa3f92b2c0359265a1755316c64717dec1aac876c0f1ff56cd906e8ed